SARMs

RAD-140 (Testolone)

Evidence: animal_plus_anecdotal

Mechanism of Action

RAD-140 is a potent nonsteroidal SARM with high oral bioavailability and selectivity for muscle and bone AR over prostate. It acts as a full agonist at the AR in muscle tissue, promoting nitrogen retention and protein synthesis via mTOR/p70S6K pathway activation. RAD-140 also demonstrates neuroprotective properties, acting against beta-amyloid-induced neurotoxicity through AR-mediated MAPK/ERK signaling. Preclinical data show greater anabolic potency than testosterone propionate at equivalent doses with significantly reduced prostate stimulation.

Dosing Protocol

Standard: Research indicates 10-20 mg daily orally for 8-12 weeks. Phase 1 clinical trial (oncology) identified 100 mg as the maximum tolerated dose.

Maintenance: Research indicates 10 mg daily. Strong suppression expected at any dose above 5 mg.

Administration: oral

Timing: Once daily, consistent timing. Very long half-life (~60 hours) means stable plasma levels even with once-daily dosing. Morning preferred.

Duration: 8-12 week cycles. PCT mandatory due to significant HPG axis suppression.

Notes

RAD-140 is considered one of the most potent SARMs available, with strong anabolic effects but correspondingly aggressive HPG suppression and hepatotoxicity risk. The 60-hour half-life means it takes weeks to fully clear after cessation. CRITICAL: Multiple case reports in hepatology journals document RAD-140-induced cholestatic liver injury requiring hospitalization. Liver monitoring is not optional. Required bloodwork: Liver function panel (AST, ALT, GGT, bilirubin, ALP) at baseline, 2 weeks, 4 weeks, and end of cycle — more frequent than other SARMs due to hepatotoxicity risk. Total testosterone, free testosterone, LH, FSH, SHBG, estradiol. CBC. Lipid panel. Post-cycle: hormonal and liver panels at 4, 8, and 12 weeks. PCT mandatory (enclomiphene or clomiphene 4-8 weeks). Medical supervision required.

Stacking

  • MK-677 (GH secretagogue for enhanced recovery and countering suppression symptoms)
  • Cardarine GW-501516 (endurance)
  • NAC / TUDCA (liver protection — essential)

Interactions

  • Testosterone / AAS [MEDIUM] — Additive HPG suppression. RAD-140 is highly suppressive on its own.
  • Hepatotoxic agents [HIGH] — Multiple case reports of RAD-140-induced severe liver injury including cholestasis and drug-induced liver injury (DILI).
  • CYP3A4 substrates [LOW] — RAD-140 may interact with CYP450 enzymes based on preclinical data.

Contraindications

  • Pre-existing liver disease
  • Androgen-sensitive cancers
  • Cardiovascular disease (LDL elevation concern)
  • Pregnancy and breastfeeding
  • Individuals under 21
  • Athletes subject to anti-doping testing

Side Effects

  • Significant testosterone suppression
  • Hepatotoxicity (multiple published case reports of drug-induced liver injury)
  • HDL suppression and LDL elevation
  • Aggression and mood changes
  • Hair shedding (androgenic effect despite 'selective' designation)
  • Insomnia
  • Headache

Key Papers

  • 10.1021/ml1002508
  • 10.1016/j.clbc.2021.08.003
  • 10.1089/end.2013.0159

Source Quality

Not FDA-approved. Research chemical only — third-party tested COA with HPLC verification mandatory. Phase 1 clinical trial completed for metastatic breast cancer (NCT03088527). High risk of adulterated products in the consumer market.

Buy RAD-140 (Testolone)

If you want to source it today, here’s a fast Amazon search link (we may earn a small commission at no extra cost).

Search on Amazon →
Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should RAD-140 (Testolone) Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds